The MorningBrief

Everything you need. Nothing you don’t.

Scientists Find How Tau Proteins Spread in Alzheimer's

Alzheimer's affects 7 million Americans and is the most feared age-related disease among the newsletter's professional demographic. A mechanistic breakthrough identifying how Tau proteins spread — and a potential blocking strategy — is a genuine scientific advance with enormous public health implications. Addresses underrepresented science_tech category.

Scientists Find How Tau Proteins Spread in Alzheimer's
Science Daily

The Morning Brief · June 30, 2026 · Based on reporting by Science Daily

A common brain protein may be ferrying toxic Tau proteins from damaged neurons into healthy ones. Blocking that transfer could slow or stop Alzheimer's progression, according to findings published Tuesday. The disease affects roughly 7 million Americans and is among the most feared age-related conditions. Identifying the vehicle that carries Tau across neurons gives researchers a concrete intervention point they did not previously have.

Until now, scientists understood that Tau proteins — which tangle and damage neurons — spread through the brain as Alzheimer's advances, but the mechanism was unclear. This research identifies a specific protein acting as a transport vessel for those toxic packages. If that vessel can be blocked before it delivers its cargo, the spread of neuronal damage may be slowed. The findings are a mechanistic advance. Researchers have not yet announced a drug candidate or clinical trial targeting this pathway.

Sources

  • Science DailyScientists may have finally found how Alzheimer's spreads through the brain

    A common brain protein may be giving Alzheimer's disease an unexpected way to spread, carrying toxic Tau proteins from damaged neurons into healthy ones. By blocking these harmful protein packages before they spread, researchers may be able to slow or stop the disease's progression.

    Read at Science Daily

  • Scientific AmericanGene-editing startups are using CRISPR to treat diseases

    A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high cholesterol to a rare muscular disorder, representing a new wave of precision medicine.

    Read at Scientific American

More from this beat